What are the most significant ways AI is accelerating drug discovery and development in biotechnology?

Most answers highlight AI's impact on accelerating drug design, data generation, and trial processes, with some emphasizing automation, improved decision-making, and value chain transformation across biotechnology.

17 answers

Answers

  • Michael Ehlers

    Entrepreneur Partner · MPM BioImpact

    Breaking Data Silos

    Michael Ehlers says breaking down data silos across drug discovery and development teams is a significant way AI is accelerating the field, enabling agentic research across biotech processes.

    Decoding Bio · Decoding Bio · Read
  • Samir Kaul

    Founding General Partner · Khosla Ventures

    Faster patient selection

    Samir Kaul says the biggest way to compress the drug development cycle is picking better patients for trials, which lets companies enroll people quicker and raise the odds a drug works.

    The answer starts at 6:27.

    MTS · Listen on Apple Podcasts
  • Packy McCormick

    Founder · Not Boring

    Generating thousands of designs

    Packy McCormick says AI's significant contribution is generating thousands of designs rapidly, citing Claude producing about 35,000 antibody designs in a month at Divergence Labs.

    Not Boring by Packy McCormick · Not Boring by Packy McCormick · Read
  • Benjamine Liu

    CEO and Co-founder at Formation Bio · Formation Bio

    Target matching & trial acceleration

    Benjamine Liu says his firm's AI tools help match the right drug target to the right indication, design studies, and run trials faster, alongside drug development capabilities.

    The answer starts at 25:52.

    MTS · Listen on Apple Podcasts
  • Kevin Weil

    CEO

    Automated Labs Generating Data

    Kevin Weil says AI models are data-poor in the sciences, so the way to make progress is to build large-scale automated labs that generate data at volume to make AI models better in science.

    The answer starts at 11:01.

    MTS · Listen on Apple Podcasts
  • Stephen Hoge

    President · Moderna

    Speeding design productivity

    Stephen Hoge says the case for optimism about AI in biotech starts with productivity, since AI accelerates tasks like sequence and protein design and trial enrollment that once took a whole team, and that productivity gain alone should have a huge impact on addressing health.

    Blackstone · Watch on YouTube
  • Harry Stebbings

    Founder · 20vc

    Automating wet labs

    Harry Stebbings says wet labs are going to become automatable, with an AI brain reasoning over large data sets in ways a single human can't, which he expects to accelerate the pace of drug discovery.

    20VC with Harry Stebbings · Watch on YouTube
  • Joshua Weiner

    Senior Vice President Consumer Engagement & Analytics · Cvs Health

    Molecular generation

    Joshua Weiner says his company CHAI has started on molecular generation because he sees it as the apex for the other things that can happen around it.

    The answer starts at 20:48.

    Stanford Online: University Courses & Lectures · Listen on Apple Podcasts
  • Sam Rahman

    Portfolio Manager & Partner · Hedgeye Asset Management, Llc

    Better efficacy & side-effect profiles

    Sam Rahman says AI can be used to create molecules and biological compounds with better side-effect profiles and better efficacy, and that AI can improve and optimize drug R&D so better products reach the market faster.

    New York Stock Exchange · Watch on YouTube
  • Nworah Ayogu

    Partner · Thrive Capital

    Across the entire value chain

    Nworah Ayogu says AI's effect on drug discovery will change the entire value chain, extending beyond discovery to manufacturing, clinical trials and commercialization.

    Sourcery with Molly O'Shea · Watch on YouTube
  • Alex Zhavoronkov

    Chief Executive Officer and Chief Business Officer · Insilico Medicine

    Generative models & automation

    Zhavoronkov posted that "prompt to drug is now possible in low-moderate novelty space."

    Where Tech Meets Bio · Where Tech Meets Bio · Read
  • Peter H. Diamandis

    Founder & Curator · Abundance360

    Parallel organoid testing

    Peter H. Diamandis cites Parallel Bio's organoids, which he says got FDA approval to skip animal trials because testing drugs on them in parallel is more predictive of how drugs behave in real human bodies.

    The answer starts at 17:20.

    Moonshots with Peter Diamandis · Listen on Apple Podcasts
  • Mukhtar Ahmed

    Chief Executive Officer · BC Platforms

    Improving decision quality

    Mukhtar Ahmed says the next wave of AI in biopharma should focus on helping organizations decide which options deserve resources, arguing technology creates more value when applied to an explicit decision framework.

    The answer starts at 15:17.

    The AI in Business Podcast · Listen on Apple Podcasts
  • Palmer Luckey

    Founder · Anduril Industries

    Digital twin cell simulations

    Palmer Luckey says AI will be used to train digital twins of cells and then run exhaustive searches of intervention space to find how to move a diseased cell to a healthy state, which he says turns biology problems into search problems.

    The answer starts at 14:20.

    ASI pill · Listen on Apple Podcasts
  • Sylke Poehling, PhD

    SVP and Global Head: Therapeutic Modalities, pRED; Roche Gene Therapy Center of Excellence · Roche

    Designing molecular sequences

    Sylke Poehling says AI's clearest value is in design, such as building and testing large libraries of AAV capsid variants in parallel so a model can learn which sequences have the needed properties, because experiments close to a sequence can be run at scale.

    Life Science Connect · Watch on YouTube
  • Olivier Litzka

    Partner · Andera Partners

    Improving every step

    Olivier Litzka says most biotech companies now use AI at every single development step, in one extent or another, and that AI can already significantly improve every single step.

    Life Science Connect · Watch on YouTube
  • Fiona H. Marshall

    President, Biomedical Research · Novartis

    New target discovery

    Fiona H. Marshall says one area she is most excited about is using AI to discover new biology and new targets, citing a new department called Target Identification that uses AI to discover new targets.

    Vanguards of Healthcare by Bloomberg Intelligence · Vanguards of Healthcare by Bloomberg Intelligence · Listen at 45:50

More Biotechnology questions

View all →